全球宠物癌症治疗市场规模、份额、成长分析，依治疗（化疗、放射治疗）、按动物（狗、猫）、按应用（淋巴瘤、肥大细胞癌）-产业预测 2024-2031

2022年全球宠物癌症治疗市场规模为2.7391亿美元，预计将从2023年的3.024亿美元增长到2031年的6.6731亿美元，在预测期内（2024-2031年）复合年增长率为10.4%。

全球宠物癌症治疗市场在更广泛的宠物医疗保健领域内的关注和创新正在显着激增。随着宠物主人越来越重视动物伙伴的福祉，对宠物有效的癌症治疗方案的需求也随之增加。人们对宠物健康意识的增强以及为宠物提供最佳护理的愿望推动了这一趋势。市场参与者正在透过开发专门针对宠物的新疗法来回应，为被诊断出患有癌症的动物带来增强结果和改善生活品质的希望。此外，兽医肿瘤学的进步有助于加深对宠物癌症的了解，促进标靶治疗的发展。整体而言，宠物癌症治疗市场呈现出一个充满活力的格局，同情心和科学进步汇聚在一起，以满足心爱的动物伙伴独特的医疗保健需求。

目录

执行摘要

• 市场概况
• 命运之轮

研究方法论

• 资讯采购
• 二手和主要资料来源
• 市场规模估计
• 市场假设与限制

母公司市场分析

• 市场概况
• 市场规模
• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战

主要市场洞察

• 技术分析
• 定价分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• 启动分析
• 原料分析
• 创新矩阵
• 管道产品分析
• 总体经济指标
• 顶级投资分析
• 成功的关键因素
• 竞争程度

市场动态与展望

• 市场动态
  • 司机
  • 机会
  • 限制
  • 挑战
• 监管环境
• 波特分析
• 对未来颠覆的特别见解

按疗法分類的全球宠物癌症治疗市场

• 市场概况
• 化疗
• 放射治疗
• 免疫疗法
• 标靶治疗
• 其他疗法

全球宠物癌症治疗市场（按动物）

• 市场概况
• 小狗
• 猫
• 其他动物

全球宠物癌症治疗市场（按应用）

• 市场概况
• 淋巴瘤
• 肥大细胞癌
• 黑色素瘤
• 乳房
• 和鳞状细胞癌
• 其他应用

全球宠物癌症治疗市场规模（按地区）

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 拉丁美洲其他地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • MEA 的其余部分

竞争格局

• 前 5 名玩家比较
• 2021 年关键参与者的市场定位
• 主要市场参与者所采取的策略
• 最佳制胜策略
• 近期市集活动
• 主要公司市占率（%），2021年

主要公司简介

• Aratana Therapeutics (US)
• Elanco Animal Health (US)
• Vetivax (US)
• Anivive Lifesciences (US)
• Regeneus (Australia)
• Qbiotics (Australia)
• Zoetis (US)
• VetDC (US)
• AB Science (France)
• Merial (France)
• VET Therapeutics (US)
• Vet Cancer Group (US)
• VetriScience (US)
• Vetnostics (Australia)
• Veterinary Cancer Group (US)
• PetCure Oncology (US)
• Veterinary Cancer Society (US)
• PetCure Oncology (US)
• Oasmia Pharmaceutical (Sweden)

Global Pet Cancer Therapeutics Market size was valued at USD 273.91 million in 2022 and is poised to grow from USD 302.40 million in 2023 to USD 667.31 million by 2031, growing at a CAGR of 10.4% during the forecast period (2024-2031).

The global market for pet cancer therapeutics is experiencing a significant surge in attention and innovation within the broader realm of pet healthcare. With pet owners placing greater emphasis on the well-being of their animal companions, the demand for effective cancer treatment options for pets has risen. This trend is fueled by an increasing awareness of pet health and the desire to provide optimal care for pets. Market players are responding by developing new therapeutics specifically tailored to pets, offering hope for enhanced outcomes and improved quality of life for animals diagnosed with cancer. Furthermore, advancements in veterinary oncology are contributing to a deeper understanding of cancer in pets, facilitating the development of targeted therapies. Overall, the pet cancer therapeutics market represents a dynamic landscape where compassion and scientific advancement converge to address the distinctive healthcare needs of beloved animal companions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pet Cancer Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pet Cancer Therapeutics Market Segmental Analysis

The global pet cancer therapeutics market is segmented into four segments therapy, animal, application and region. Based on therapy the market is segmented as, chemotherapy, radiation therapy, immunotherapy, targeted therapy, and other therapies. Based on animal, the market is bifurcated as, dogs, cats, other animals. On the basis of application the market is segmented as, lymphoma, mast cell cancer, melanoma, mammary, and squamous cell cancer, other applications. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Pet Cancer Therapeutics Market

The burgeoning global pet cancer therapeutics market is significantly fueled by the rising phenomenon of pet humanization, wherein pet owners increasingly perceive their furry companions as indispensable family members. This shift in perspective drives a notable surge in investments towards advanced healthcare solutions, particularly cancer treatments, for pets. Consequently, there's a heightened demand for compassionate and efficacious cancer therapeutics specifically designed for pets, fostering innovation and expansion within the market.

Restraints in the Global Pet Cancer Therapeutics Market

A major obstacle in the worldwide pet cancer therapeutics sector is the exorbitant expense tied to cancer care for pets, covering diagnostics, surgeries, radiation therapy, and medication. These costs can impose significant financial strain on pet guardians, restricting access to advanced cancer treatments and forcing them to make tough decisions regarding their pets' care options. Consequently, despite the growing demand and awareness surrounding pet cancer therapeutics, affordability emerges as a pivotal concern, influencing market dynamics and the accessibility of these treatments.

Market Trends of the Global Pet Cancer Therapeutics Market

A notable trend in the global market for pet cancer therapeutics is the increasing focus on personalized treatment strategies, acknowledging the individuality of each pet's cancer diagnosis and therapeutic needs. This emphasis is fueling the need for customized therapeutic options, encompassing precision medicine and targeted therapies, as well as advancements in diagnostic techniques like genetic profiling and molecular testing. As a result, treatment regimens can be tailored to the unique features of a pet's cancer, enhancing treatment effectiveness and possibly minimizing adverse effects. This transition towards personalized care underscores a rising dedication to improving the standard of care and outcomes for pets grappling with cancer.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Pet Cancer Therapeutics Market by Therapy

• Market Overview
• Chemotherapy
• Radiation therapy
• Immunotherapy
• Targeted Therapy
• and Other Therapies

Global Pet Cancer Therapeutics Market by Animal

• Market Overview
• Dogs
• Cats
• Other Animals

Global Pet Cancer Therapeutics Market by Application

• Market Overview
• Lymphoma
• Mast Cell Cancer
• Melanoma
• Mammary
• and Squamous Cell Cancer
• Other Applications

Global Pet Cancer Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Aratana Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetivax (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anivive Lifesciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneus (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qbiotics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetDC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AB Science (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merial (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VET Therapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vet Cancer Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• VetriScience (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetnostics (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veterinary Cancer Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetCure Oncology (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Veterinary Cancer Society (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PetCure Oncology (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oasmia Pharmaceutical (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments